医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SIRION Biotech to Participate in Major International Industry Conferences

2019年10月01日 PM09:00
このエントリーをはてなブックマークに追加


 

MARTINSRIED, Germany

SIRION Biotech GmbH (“SIRION”) today announced its participation in major international conferences this October. SIRION, offering the most comprehensive portfolio of custom viral vectors for preclinical and clinical studies, will present at the Cell and Gene Meeting on the Mesa in Carlsbad, California on October 2 – 4, and exhibit at the European Biotech and Pharma Partnering Conference in Osaka, Japan on October 8, BioJapan in Pacifico Yokohama, Japan on October 9 – 11, and the ESGCT 27th Annual Congress on October 22 – 25 in Barcelona, Spain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191001005658/en/

Dr. Christina Ureche working with Japanese and Korean markets (Photo: Business Wire)

Dr. Christina Ureche working with Japanese and Korean markets (Photo: Business Wire)

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference gathering industry leaders and decision-makers to bring forward the state-of-the-art research developments to medicines. Dr. Christian Thirion, CEO, will discuss novel therapeutic viral vectors and technology platforms based on lentivirus, adenovirus, and adeno-associated viruses, which expedite gene therapy research and advances drug development, during his company presentation on Wednesday, October 2 at 4:45 p.m. in the Cognate Bioservices Ballroom at the Park Hyatt Aviara Resort in Carlsbad, CA. A live video webcast of all company presentations will be available at: http://www.meetingonthemesa.com/webcast and will also be published on the conference website shortly after the event.

The Osaka European Biotech and Pharma Partnering Conference offers business contacts to industry professionals who are looking for potential partners in the EU and Japan to ensure sustainable business development and growth. BioJapan is Asia’s premier partnering event for the global biotech industry. SIRION will be exhibiting at both of these meetings, at the Pacifico Yokohama at D-53. Organized by European Society of Gene and Cell Therapy, the ESGCT Annual Congress in Barcelona promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology, and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe. SIRION will exhibit at this meeting at the Barcelona INTERNATIONAL Convention Centre ­­­at level P2, booth 20 as part of the ABC of AAV, offering everything you need for gene therapy in one place.

About SIRION Biotech GmbH
SIRION Biotech founded in 2005 in Martinsried near Munich, Germany with the goal to skyrocket a new generation of viral vector technologies for gene & cell therapy as well as vaccine development. SIRION advances novel therapeutic viral vectors and uses proprietary technology platforms based on lenti-, adeno-, and adeno-associated viruses, to facilitate its partners’ successes in drug development. SIRION’s LentiBOOSTTM transduction reagent is actively used to enhance, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects focus on tissue targeting and immune escape of capsids to accelerate a next generation therapeutics for gene therapy companies. For additional information, please visit http://www.sirion-biotech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191001005658/en/

CONTACT

Corporate Contact:

Carl Christel, PhD, VP USA

SIRION Biotech International Inc.

(857) 284-1844

christel@sirion-biotech.de

BD & Licensing Contact

Sabine Ott, Ph.D., VP Licensing & BD

SIRION Biotech GmbH

+49 89-700-96199-19

Ott@sirion-biotech.com

Media Contact:

Lisa DeScenza

Assistant Vice President, Integrated Communications

LaVoieHealthScience

(978) 395-5970

ldescenza@lavoiehealthscience.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 武田将呈报ICLUSIG® (ponatinib)临床试验项目数据,这些数据有望改变慢性期CML治疗的实践
  • 武田薬品、高リスクMDS患者でpevonedistatとアザシチジンの併用療法を検討する第2相試験の有力なデータを発表
  • 武田发布Pevonedistat联合阿扎胞苷治疗较高危MDS患者2期试验的有力数据
  • 武田薬品が慢性期CMLの治療を変え得るアイクルシグ(ポナチニブ)臨床試験プログラムのデータを発表へ
  • SETi to Start Online Sales for Surface Disinfection Device and Portable Air Purifier with Violeds Technology to Enable Disinfection of New Coronavirus